AU3390297A - Uses of a chemokine receptor for inhibiting hiv-1 infection - Google Patents

Uses of a chemokine receptor for inhibiting hiv-1 infection

Info

Publication number
AU3390297A
AU3390297A AU33902/97A AU3390297A AU3390297A AU 3390297 A AU3390297 A AU 3390297A AU 33902/97 A AU33902/97 A AU 33902/97A AU 3390297 A AU3390297 A AU 3390297A AU 3390297 A AU3390297 A AU 3390297A
Authority
AU
Australia
Prior art keywords
infection
chemokine receptor
inhibiting hiv
hiv
inhibiting
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU33902/97A
Inventor
Graham P. Allaway
Tatjana Dragic
Virginia M. Litwin
Paul J. Maddon
John P Moore
Alexandra Trkola
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Progenics Pharmaceuticals Inc
Aaron Diamond AIDS Research Center
Original Assignee
Progenics Pharmaceuticals Inc
Aaron Diamond AIDS Research Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Progenics Pharmaceuticals Inc, Aaron Diamond AIDS Research Center filed Critical Progenics Pharmaceuticals Inc
Publication of AU3390297A publication Critical patent/AU3390297A/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7158—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for chemokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
AU33902/97A 1996-06-14 1997-06-13 Uses of a chemokine receptor for inhibiting hiv-1 infection Abandoned AU3390297A (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US66509096A 1996-06-14 1996-06-14
US1994196P 1996-06-14 1996-06-14
US08665090 1996-06-14
US60019941 1996-06-14
PCT/US1997/010233 WO1997047318A1 (en) 1996-06-14 1997-06-13 Uses of a chemokine receptor for inhibiting hiv-1 infection

Publications (1)

Publication Number Publication Date
AU3390297A true AU3390297A (en) 1998-01-07

Family

ID=26692788

Family Applications (2)

Application Number Title Priority Date Filing Date
AU33902/97A Abandoned AU3390297A (en) 1996-06-14 1997-06-13 Uses of a chemokine receptor for inhibiting hiv-1 infection
AU34026/97A Ceased AU735460B2 (en) 1996-06-14 1997-06-13 Uses of a chemokine receptor for inhibiting HIV-1 infection

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU34026/97A Ceased AU735460B2 (en) 1996-06-14 1997-06-13 Uses of a chemokine receptor for inhibiting HIV-1 infection

Country Status (5)

Country Link
EP (1) EP0956044A4 (en)
JP (1) JP4183754B2 (en)
AU (2) AU3390297A (en)
CA (1) CA2257991A1 (en)
WO (2) WO1997047319A1 (en)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6025154A (en) 1995-06-06 2000-02-15 Human Genome Sciences, Inc. Polynucleotides encoding human G-protein chemokine receptor HDGNR10
US6743594B1 (en) 1995-06-06 2004-06-01 Human Genome Sciences, Inc. Methods of screening using human G-protein chemokine receptor HDGNR10 (CCR5)
ES2325042T3 (en) 1995-06-07 2009-08-24 Progenics Pharmaceuticals, Inc. MONOCLONAL ANTIBODY TO INHIBIT THE GLUSOPROTEIN MEMBRANE FUSION OF HIV-1 ENVELOPE.
US6265184B1 (en) 1995-12-20 2001-07-24 Icos Corporation Polynucleotides encoding chemokine receptor 88C
US7118859B2 (en) 1996-01-17 2006-10-10 Progenics Pharmaceuticals, Inc. Methods for inhibiting HIV-1 infection
US6107019A (en) * 1996-06-14 2000-08-22 Progenics Pharmaceuticals, Inc. Method for preventing HIV-1 infection of CD4+ cells
US7858298B1 (en) 1996-04-01 2010-12-28 Progenics Pharmaceuticals Inc. Methods of inhibiting human immunodeficiency virus type 1 (HIV-1) infection through the administration of CCR5 chemokine receptor antagonists
EP0975749A2 (en) 1996-05-28 2000-02-02 THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES Cc chemokine receptor 5, antibodies thereto, transgenic animals
US6528625B1 (en) 1996-10-28 2003-03-04 Millennium Pharmaceuticals, Inc. Anti-CCR5 antibodies and kits comprising same
US6153431A (en) * 1997-05-30 2000-11-28 Fond Mondiale Rech & Prev Sida Human immunodeficiency virus co-receptor variants associated with resistance to virus infection
US6399078B1 (en) 1998-06-01 2002-06-04 University Of Maryland Biotechnology Institute Chemokine—glycosaminoglycan complexes and their use in treating or preventing receptor mediated diseases
US6312689B1 (en) 1998-07-23 2001-11-06 Millennium Pharmaceuticals, Inc. Anti-CCR2 antibodies and methods of use therefor
US6727349B1 (en) 1998-07-23 2004-04-27 Millennium Pharmaceuticals, Inc. Recombinant anti-CCR2 antibodies and methods of use therefor
US6696550B2 (en) 1998-07-23 2004-02-24 Millennium Pharmaceuticals, Inc. Humanized anti-CCR2 antibodies and methods of use therefor
WO2000029556A2 (en) * 1998-11-17 2000-05-25 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services Identification of glycosphingolipids that promote hiv-1 entry into cells
EP1900376A3 (en) * 1998-12-16 2008-10-15 Progenics Pharmaceuticals, Inc. Synergistic inhibition of HIV-1 fusion and attachment, compsitions and antobodies thereto
JP2002538771A (en) * 1998-12-16 2002-11-19 プロジェニクス・ファーマスーティカルズ・インコーポレイテッド Synergistic inhibition of HIV-1 fusion and adhesion, compositions and antibodies therefor
AU2722600A (en) * 1999-01-08 2000-07-24 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Inhibition of cd4-ccr5 interaction
JP2000229997A (en) 1999-02-10 2000-08-22 Nissui Pharm Co Ltd Cyclic peptide and aids vaccine
US7115262B1 (en) 1999-03-16 2006-10-03 The United States Of America As Represented By The Department Of Health And Human Services Chimeric protein for prevention and treatment of HIV infection
ES2313886T3 (en) * 1999-03-16 2009-03-16 The Government Of The Usa, As Represented By The Secretary, Department Of Health And Human Services NEW CHEMICAL PROTEIN FOR THE PREVENTION AND TREATMENT OF HIV INFECTION.
AU6941000A (en) * 1999-08-27 2001-03-26 United States Of America, Represented By The Secretary, Department Of Health And Human Services, The Polypeptides that bind hiv gp120 and related nucleic acids, antibodies, compositions, and methods of use
US7304127B2 (en) 1999-08-27 2007-12-04 United States Of America As Represented By The Secretary, Department Of Health And Human Services Polypeptides that bind HIV gp120 and related nucleic acids, antibodies, compositions, and methods of use
CA2389196A1 (en) 1999-10-28 2001-05-03 Nissui Pharmaceutical Co., Ltd. Cyclic peptides and aids vaccines
US20030049251A1 (en) * 1999-12-08 2003-03-13 Barbas Carlos F. Methods and compositions useful for inhibiting ccr5-dependent infection of cells by hiv-1
GB9930443D0 (en) * 1999-12-22 2000-02-16 King S College London Novel use of heat shock proteins
US7138119B2 (en) 2000-09-15 2006-11-21 Progenics Pharmaceuticals, Inc. Compositions and methods for inhibition of HIV-1 infection
US7175988B2 (en) 2001-02-09 2007-02-13 Human Genome Sciences, Inc. Human G-protein Chemokine Receptor (CCR5) HDGNR10
US7060273B2 (en) 2001-04-06 2006-06-13 Progenics Pharmaceuticals, Inc. Methods for inhibiting HIV-1 infection
US7393934B2 (en) 2001-12-21 2008-07-01 Human Genome Sciences, Inc. Human G-protein chemokine receptor (CCR5) HDGNR10
US7122185B2 (en) 2002-02-22 2006-10-17 Progenics Pharmaceuticals, Inc. Anti-CCR5 antibody
BRPI0317463B8 (en) 2002-12-19 2021-05-25 Scripps Research Inst compound, pharmaceutical composition comprising the same and use of said compound in the preparation of a medicament for treating a transthyretin amyloid disease
EP1723178A4 (en) 2004-03-12 2007-12-12 Human Genome Sciences Inc Human g-protein chemokine receptor (ccr5) hdgnr10
CA2616189C (en) 2005-07-22 2019-03-26 Progenics Pharmaceuticals, Inc. Methods for reducing viral load in hiv-1-infected patients

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5126433A (en) * 1986-08-21 1992-06-30 The Trustees Of Columbia University In The City Of New York Soluble forms of the t cell surface protein cd4
US5869624A (en) * 1993-03-26 1999-02-09 Progenics Pharmaceuticals, Inc. HIV-1 vaccines, antibody compositions related thereto, and therapeutic and prophylactic uses thereof
CA2178495A1 (en) * 1993-12-17 1995-06-22 Graham P. Allaway Methods for using resonance energy transfer-based assay of hiv-1 envelope clycoprotein-mediated membrane fusion, and kits for practicing same
WO1996039437A1 (en) * 1995-06-06 1996-12-12 Human Genome Sciences, Inc. Human g-protein chemokine receptor hdgnr10
ES2325042T3 (en) * 1995-06-07 2009-08-24 Progenics Pharmaceuticals, Inc. MONOCLONAL ANTIBODY TO INHIBIT THE GLUSOPROTEIN MEMBRANE FUSION OF HIV-1 ENVELOPE.
ATE428785T1 (en) * 1996-03-01 2009-05-15 Euroscreen Sa ACTIVE AND INACTIVE CC CHEMOKINE RECEPTORS AND NUCLEIC ACID MOLECULES THAT CODE FOR THIS RECEPTOR

Also Published As

Publication number Publication date
CA2257991A1 (en) 1997-12-18
WO1997047319A1 (en) 1997-12-18
EP0956044A1 (en) 1999-11-17
EP0956044A4 (en) 2005-01-05
WO1997047318A1 (en) 1997-12-18
AU3402697A (en) 1998-01-07
JP4183754B2 (en) 2008-11-19
JP2001503608A (en) 2001-03-21
AU735460B2 (en) 2001-07-12

Similar Documents

Publication Publication Date Title
AU3390297A (en) Uses of a chemokine receptor for inhibiting hiv-1 infection
AU6450496A (en) Chuck
AU6565396A (en) Surgical clamping mechanism
AU2414795A (en) A direct conversion receiver
AU4776996A (en) Compound sanitary napkin
AU2571097A (en) Process for the preparation of creep-resistant polypropylene block copolymers
AU7093396A (en) Medicament conversion system
AU7051698A (en) Ring clamp for connecting two tubes
AU1030195A (en) Hiv retrovirus infection inhibitor capable of interacting with cd26 receptor
AU2258197A (en) Release system for treatment of a broken jaw
AU1408300A (en) Hiv infection inhibitors
AU5195896A (en) Analog-to-digital converter comparator reference arrangement
AU6748196A (en) Receptor
AU1750497A (en) Compounds capable of inhibiting hiv-1 infection
GB9621974D0 (en) HIV integrase inhibitors
ZA96722B (en) Combination therapy for hiv infection
AU7361096A (en) Concentric dual elbow
AU5934696A (en) Monolithic analog-to-digital converter
AU8232498A (en) Gripping aid
AU5033296A (en) Antidepressant heteroarylaminoalkyl derivatives of naphthyl-monazines
AU1879397A (en) A process for the preparation of copolymers
AU6271098A (en) Hiv integrase inhibitors
AU5100696A (en) Specific hiv-1 group o antigens
AU3857395A (en) Catalyst system for the preparation of a rubber-like copolymer
AU5290496A (en) Pressure converter (b)